GENUV established "ATRIVIEWTM", a screening platform using neural stem cells for the identification of substances that provide a neuroprotective and differentiating effect on neurons. Through this screening technology, GENUV succeeded in discovering a small molecule ‘repurposed’ drug candidate, SNR 1611, that shows efficacy in neurogenesis and neural homeostasis recovery.
GENUV has begun a phase 1/2a clinical trial on its Amyotrophic Lateral Sclerosis (ALS) drug candidate, SNR1611, in Korea. Samsung Medical Center, Yonsei Severance Hospital, Seoul Asan Medical Center and Korea University Anam Hospital initiated the recruitment of patient and the first patient was enrolled on June 24, 2020.
To view original article, please click here.